论文部分内容阅读
目的:探讨普米克令舒联合万托林在急性期慢性阻塞性肺疾病(COPD)临床治疗中的应用价值。方法 :选取2010年6月至2012年6月来我院接受急性期COPD治疗的患者140例,其中70例患者采用常规治疗方法进行治疗,作为对照组,剩下的70例患者在使用普米克令舒联合万托林雾化吸入治疗方法进行治疗,作为观察组,分别以两组患者的FEV1、FVC占预计值的百分比、FEV1/FVC和症状改善情况作为临床观察指标,并使用SPSS 13.0软件包进行统计学分析。结果 :观察组患者的FEV1、FVC占预计值的百分比、FEV1/FVC均优于对照组患者,P<0.05或P<0.01;观察组患者治疗后的COPD症状改善情况明显优于对照组患者,P<0.01。结论 :普米克令舒联合万托林雾化吸入治疗法可有效的改善COPD患者的FEV1、FVC占预计值的百分比、FEV1/FVC值,对于急性期COPD临床症状的改善和治疗具有重要的意义,具有推广应用价值。
Objective: To investigate the clinical value of pulmicort and ligustine in the treatment of acute obstructive pulmonary disease (COPD). Methods: From June 2010 to June 2012 in our hospital to accept acute COPD treatment of 140 patients, of which 70 patients treated by conventional treatment, as the control group, the remaining 70 patients in the use of Pulmic As the observation group, FEV1, FVC as a percentage of expected value, FEV1 / FVC and symptom improvement were taken as clinical observation indicators respectively in the observation group and SPSS 13.0 software Package for statistical analysis. Results: The FEV1 and FVC in the observation group accounted for the percentage of the predicted value, FEV1 / FVC were superior to the control group, P <0.05 or P <0.01; the observation group patients treated COPD symptom improvement was significantly better than the control group, P <0.01. CONCLUSION: Pulmicort respules combined with Vanthorid Atomizing inhalation therapy can effectively improve FEV1 and FVC in COPD patients as a percentage of predicted value and FEV1 / FVC, which is of great significance for the improvement and treatment of clinical symptoms in acute COPD , With the promotion and application value.